LARGER VIALS = LARGER SAVINGS PER mg

ARA-290

ARA-290

$66.00
$66.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

ARA-290

ARA-290

$66.00
$66.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

ARA-290 is a synthetic peptide derived from erythropoietin (EPO) that selectively targets the innate repair receptor (IRR) without stimulating erythropoiesis. It has been studied for its potential to reduce inflammation, alleviate neuropathic pain, and promote tissue repair.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

ARA-290 (also known as Cibinetide) is an 11–amino acid synthetic peptide derived from the B-helix of erythropoietin (EPO). Unlike full EPO, ARA-290 does not stimulate erythropoiesis (red blood cell production). Instead, it selectively binds the innate repair receptor (IRR), a heterodimer of the EPO receptor (EPOR) and CD131. Through this interaction, ARA-290 triggers tissue-protective, anti-inflammatory, and pro-regenerative pathways without the hematopoietic side effects of EPO.

Structure

  • Type: Synthetic 11–amino acid peptide
  • Origin: B-helix of erythropoietin (EPO)
  • Activity: IRR agonist, tissue-protective, non-erythropoietic

Research

Inflammation & Neuroprotection

ARA-290 has demonstrated strong anti-inflammatory effects in models of neuropathy, ischemia, and tissue injury. By activating the IRR, it downregulates pro-inflammatory cytokines, reduces oxidative stress, and limits tissue damage.

In animal studies, ARA-290 improved nerve conduction velocity, myelin repair, and small-fiber density, supporting its role in neuropathic pain and peripheral nerve injury.

Metabolic Disorders & Sarcoidosis

Clinical trials have shown ARA-290 can improve insulin sensitivity, lipid metabolism, and markers of chronic inflammation. In patients with sarcoidosis-associated small fiber neuropathy (SFN), treatment led to improved neuropathic pain scores and corneal nerve fiber density.

Ischemia & Organ Protection

In models of cardiac and renal ischemia, ARA-290 reduced tissue damage by decreasing apoptosis and improving vascular integrity. It has been proposed as a protective agent in ischemia-reperfusion injury and chronic kidney disease.

Mechanism of Action

  • Selectively binds the innate repair receptor (EPOR/CD131 heterodimer)
  • Activates tissue-protective pathways without affecting hematocrit
  • Downregulates inflammatory mediators while promoting angiogenesis, cell survival, and repair

Summary

ARA-290 (Cibinetide) is a tissue-protective peptide derived from EPO that activates the innate repair receptor. Research highlights include:

  • Reduction of neuropathic pain and improvement of small-fiber neuropathy
  • Anti-inflammatory and anti-apoptotic properties
  • Organ protection in ischemia and metabolic disease models
  • Distinct advantage of being non-erythropoietic (no effect on hematocrit or clotting risk)

This makes ARA-290 a promising therapeutic candidate for chronic inflammation, neuropathic pain, ischemic injury, and metabolic disorders.

This product is provided as a lyophilized peptide. Store at 2–8 °C in a sealed container, protected from light and moisture. For long-term preservation, store unopened vials at −20 °C. After reconstitution, solutions should be prepared under sterile conditions, stored at refrigerated temperature, and used promptly. Avoid repeated freeze–thaw cycles to maintain peptide stability.

1. Brines M, Cerami A. Discovering erythropoietin’s non-erythropoietic functions: innate repair receptor activation by ARA-290. Nephrol Dial Transplant. 2012;27(5):1675–1680. doi:10.1093/ndt/gfs037

2. Heij L, Niesters M, Swartjes M, et al. Cibinetide (ARA-290), a non-erythropoietic EPO analogue, improves neuropathic pain and corneal nerve fiber density in sarcoidosis. Mol Med. 2012;18(1):1430–1436. doi:10.2119/molmed.2012.00223

3. van Velzen M, Heij L, Niesters M, et al. Cibinetide improves corneal nerve fiber density in sarcoidosis-associated small fiber neuropathy. Invest Ophthalmol Vis Sci. 2014;55(10):6084–6091. doi:10.1167/iovs.14-14456

4. Brines M, Patel NS, Villa P, et al. Non-erythropoietic tissue protection by EPO derivatives in ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2008;105(31):10925–10930. doi:10.1073/pnas.0805594105

5. Dahan A, et al. ARA-290 alleviates neuropathic pain and improves nerve repair in preclinical models. Pain. 2013;154(8):1464–1473. doi:10.1016/j.pain.2013.05.009

6. Brines M, Ghali JK, Cerami A. The erythropoietin-derived peptide ARA-290 in metabolic disease. Cardiovasc Diabetol. 2014;13:32. doi:10.1186/1475-2840-13-32

7. Niesters M, et al. Cibinetide modulates the immune response in sarcoidosis patients. Respir Med. 2014;108(2):282–289. doi:10.1016/j.rmed.2013.11.003

8. Patel NS, Kerrigan J, Brines M, et al. Erythropoietin derivatives protect the kidney from ischemia-reperfusion injury. J Am Soc Nephrol. 2004;15(8):2115–2124. doi:10.1097/01.ASN.0000135056.21452.98

9. Swartjes M, Niesters M, Heij L, et al. Cibinetide as a potential treatment for sarcoidosis-associated neuropathic pain. Pain Pract. 2015;15(4):382–389. doi:10.1111/papr.12203

10. Brines M, Cerami A. The innate repair receptor as a therapeutic target for inflammatory and degenerative disease. Nat Rev Drug Discov. 2012;11(9):698–710. doi:10.1038/nrd3805